Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial

BACKGROUND: VRC01 is an HIV-1 CD4 binding site broadly neutralizing antibody (bnAb) that is active against a broad range of HIV-1 primary isolates in vitro and protects against simian-human immunodeficiency virus (SHIV) when delivered parenterally to nonhuman primates. It has been shown to be safe a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:PLoS Med
Autors principals: Mayer, Kenneth H., Seaton, Kelly E., Huang, Yunda, Grunenberg, Nicole, Isaacs, Abby, Allen, Mary, Ledgerwood, Julie E., Frank, Ian, Sobieszczyk, Magdalena E., Baden, Lindsey R., Rodriguez, Benigno, Van Tieu, Hong, Tomaras, Georgia D., Deal, Aaron, Goodman, Derrick, Bailer, Robert T., Ferrari, Guido, Jensen, Ryan, Hural, John, Graham, Barney S., Mascola, John R., Corey, Lawrence, Montefiori, David C.
Format: Artigo
Idioma:Inglês
Publicat: Public Library of Science 2017
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5685476/
https://ncbi.nlm.nih.gov/pubmed/29136037
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002435
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars